Last Updated: September 24, 2026

Actavis Labs Fl Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for ACTAVIS LABS FL

ACTAVIS LABS FL has eighty-three approved drugs.

There are six tentative approvals on ACTAVIS LABS FL drugs.

Summary for Actavis Labs Fl

US Patents:	0
Tradenames:	69
Ingredients:	67
NDAs:	83

Drugs and US Patents for Actavis Labs Fl

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Labs Fl Inc	PREDNISONE	prednisone	TABLET, DELAYED RELEASE;ORAL	204867-001	Apr 25, 2017		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Actavis Labs Fl Inc	NITROGLYCERIN	nitroglycerin	TABLET;SUBLINGUAL	203693-001	Oct 16, 2017		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Actavis Labs Fl Inc	DILTIAZEM HYDROCHLORIDE	diltiazem hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	074852-002	Oct 10, 1997		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Actavis Labs Fl Inc	DILTIAZEM HYDROCHLORIDE	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	077686-001	Mar 15, 2010	AB	RX	No	No		⤷ Start Trial				⤷ Start Trial
Actavis Labs Fl	ISOTRETINOIN	isotretinoin	CAPSULE;ORAL	205063-006	Mar 31, 2021	AB2	RX	No	No		⤷ Start Trial				⤷ Start Trial
Actavis Labs Fl Inc	TAMOXIFEN CITRATE	tamoxifen citrate	TABLET;ORAL	076179-001	Feb 20, 2003		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Paragraph IV (Patent) Challenges for ACTAVIS LABS FL drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Delayed-release Tablets	20 mg	➤ Subscribe	2015-06-03

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.